<DOC>
	<DOCNO>NCT00586508</DOCNO>
	<brief_summary>The purpose study evaluate enzastaurin bevacizumab treatment recurrent malignant glioma .</brief_summary>
	<brief_title>Trial Enzastaurin Bevacizumab Adults With Recurrent Malignant Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patient must least 18 year old Patient must diagnose recurrent brain tumor MRI scan Patient must willing practice adequate contraception Patient must able swallow Enzastaurin tablet whole receive Bevacizumab intravenously Patient must agree use study drug instruct study doctor staff . Women pregnant breastfeeding Patients significant heart , liver , kidney , psychiatric disease Patients active infection Patients recent bleed brain Patients take anticoagulation antiplatelet medication ( include aspirin , nonsteroidal antiinflammatories , COX2 inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>